Peer-reviewed clinical results and strong patient preference support growing use across neurology practices and emerging brain health applications

Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the peer-reviewed publication of the NEURO PMR study in the Journal of Neuroimaging. The publication comes as real-world use of the Swoop system continues to grow, with more than 3,000 brain MRI scans completed across a broad range of physician practices within the first year of Hyperfine’s office-market launch.

NEURO PMR, or Neurological Evaluation in the Office with Portable MR, is the first prospective, multicenter, real-world study to evaluate the clinical performance and patient experience of portable MRI compared with high-field MRI in outpatient neurology clinics. With respect to clinical performance, portable MRI demonstrated 92% concordance with high-field MRI in identifying the presence or absence of structural abnormality in blinded neuroradiology review, and 98% with clinical information. In addition, patients preferred portable MRI over high-field MRI by a four-to-one margin, rating it superior on all dimensions assessed in the study, including comfort, anxiety, claustrophobia, noise and overall experience.